NASDAQ
22.01.25
21:59 Uhr
0,193 US-Dollar
0,000
0,00 %
0,00 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.01. | Lyra Therapeutics, Inc. - 8-K, Current Report | 6 | SEC Filings | ||
| 13.12.24 | Lyra Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 13.11.24 | Lyra Therapeutics stock plunges to 52-week low of $0.21 | 4 | Investing.com | ||
| 13.11.24 | Lyra Therapeutics-Aktie stürzt auf 52-Wochen-Tief von 0,21 US-Dollar | 5 | Investing.com Deutsch | ||
| LYRA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.11.24 | Lyra Therapeutics GAAP EPS of -$0.18 beats by $0.02, revenue of $0.2M misses by $0.06M | 3 | Seeking Alpha | ||
| 12.11.24 | Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | 98 | GlobeNewswire (Europe) | Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension... ► Artikel lesen | |
| 12.11.24 | Lyra Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11.24 | Lyra Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.10.24 | Lyra Therapeutics schließt Patientenrekrutierung für Phase-3-Studie zur CRS-Behandlung ab | 5 | Investing.com Deutsch | ||
| 15.10.24 | Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis | 109 | GlobeNewswire (Europe) | -- Topline Results Expected Q2 2025 -- WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company... ► Artikel lesen | |
| 27.09.24 | Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings | 2 | GlobeNewswire (USA) | ||
| 26.09.24 | Aktie von Lyra Therapeutics stürzt auf 52-Wochen-Tief von 0,25 US-Dollar | 10 | Investing.com Deutsch | ||
| 26.09.24 | Lyra Therapeutics stock plunges to 52-week low of $0.25 | 3 | Investing.com | ||
| 15.08.24 | Lyra Therapeutics still sees potential in rhinosinusitis asset despite setbacks | 4 | Seeking Alpha | ||
| 15.08.24 | H.C. Wainwright holds Lyra Therapeutics stock at 'Neutral,' awaiting Phase 3 results | 1 | Investing.com | ||
| 14.08.24 | Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update | 153 | GlobeNewswire (Europe) | - Primary focus continues to be on upcoming results from ENLIGHTEN 1 Phase 3 extension study in 4Q 2024 and ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients in 1H 2025, as planned - - In parallel... ► Artikel lesen | |
| 06.05.24 | Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis | 233 | GlobeNewswire (Europe) | ENLIGHTEN 1 trial did not meet its primary endpoint Company plans to evaluate full dataset and path forward WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA)... ► Artikel lesen | |
| 30.04.24 | Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update | 173 | GlobeNewswire (Europe) | WATERTOWN, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory... ► Artikel lesen | |
| 26.04.24 | Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 275 | GlobeNewswire (Europe) | WATERTOWN, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the "Company" or "Lyra"), a clinical-stage biotech developing long-acting, anti-inflammatory sinonasal... ► Artikel lesen | |
| 21.03.24 | Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | 481 | GlobeNewswire (Europe) | -- Data from ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Anticipated Q2 2024 -- WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq:... ► Artikel lesen |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 21,170 | +0,88 % | PRESSESPIEGEL/Unternehmen: DAIMLER TRUCK, VOLKSWAGEN, BASF, BAYER, GREEN FLEXIBILITY, NEURA ROBOTICS, ITALIENISCHE STAATSBAHN, CHRONO24 | DJ PRESSESPIEGEL/Unternehmen
Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires.
DAIMLER TRUCK - Normalerweise kaufen die Kunden die Lastwagen von Daimler... ► Artikel lesen | |
| PFIZER | 25,125 | +0,56 % | Pfizer Aktie: Was Analysten zu berichten haben | Die US-amerikanische Pharmafirma Pfizer steht aktuell vor wichtigen strategischen Veränderungen. Der Konzern plant bedeutende Verkaufsaktivitäten, während die Aktie am letzten Handelstag bei 26,31 USD... ► Artikel lesen | |
| SANOFI | 100,60 | +1,75 % | JPMORGAN stuft SANOFI auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Sanofi nach einer Pharmakonferenz auf "Neutral" mit einem Kursziel von 105 Euro belassen. Mit der Veröffentlichung der Quartalszahlen... ► Artikel lesen | |
| INNOCAN PHARMA | 0,116 | +0,43 % | Innocan Pharma Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| ASSEMBLY BIOSCIENCES | 14,550 | +2,46 % | Assembly Biosciences, Inc.: Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B | - ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed - - In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 0,319 | 0,00 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia | Tonix received FDA's Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025 TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast... ► Artikel lesen | |
| NEWRON PHARMACEUTICALS | 9,720 | -0,72 % | Community-Rückblick: wO-User zu Newron Pharma nach Südkorea Deal: "2028 ist die Firma Geschichte..." | © Foto: ChatGPTDie Diskussion um Newron Pharma flammte erneut auf, nachdem die italienische Biotechfirma am 09.01. die Kooperation mit "Myung In Pharm", zwecks Vertrieb des Hoffnungsmittels Evenamide... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 0,867 | -2,91 % | Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis | SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AD... ► Artikel lesen | |
| COMPASS PATHWAYS | 3,540 | -1,67 % | Compass Pathways plc: Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer | Newly created role of Chief Patient Officer reinforces Compass' vision of working to achieve broad and equitable access to COMP360, if approved
Compass Pathways plc (Nasdaq: CMPS) ("Compass"),... ► Artikel lesen | |
| ROYALTY PHARMA | 28,940 | +0,17 % | Royalty Pharma plc: Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program | Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of greater than $100 million in 2026 growing to over $175 million... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 33,930 | -1,42 % | AKTIONÄR-Favorit BridgeBio mit Kurssprung - Startschuss zur Rally? | Das neue Jahr hätte für das US-Biotech-Unternehmen BridgeBio Pharma nicht besser starten können. Am Montag gelang dem Papier ein Kurssprung von 16 Prozent und damit ein neues Kaufsignal für die Aktie.... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 11,100 | +0,91 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors | NORWOOD, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, today... ► Artikel lesen | |
| OPUS GENETICS | 1,056 | +1,34 % | Opus Genetics, Inc.: Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy | Agreement Reached on Primary Endpoint and Phase 3 Trial Design Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| SOLIGENIX | 2,490 | 0,00 % | SOLIGENIX, INC.: Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma | FLASH2 Study opens patient enrollment PRINCETON, N.J., Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company... ► Artikel lesen | |
| AYTU BIOPHARMA | 1,570 | -100,00 % | Aytu BioPharma, Inc: Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 | DENVER, CO / ACCESSWIRE / January 6, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that... ► Artikel lesen |
Das Unternehmen LYRA THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,193 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LYRA THERAPEUTICS INC finden Sie auf Wallstreet Online.
